Tell Us What You Think

Rate your Quintiles.com experience

Subscribe to Email Based on Your Interests

Set preferences

Information Library

Connect with investigators, regulators and physicians - Phase IIIB/IV

To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.

See all

  • Sort by: Most Recent
  • Title
  • ASCO 2010 Annual Meeting

    June 4 - June 8, 2010
    Exhibit Dates: June 5 - 7, 2010 Exhibitor Booth Number: 2053

  • Incremental Cost of Otitis Media Among Children in the United States

    June 25, 2009
    Using a nationally representative data source, the study estimates the medical cost of treating otitis media among children in the US. The costs are estimated at $2 billion in 2005.

  • Patient Registries: A Taxonomy for the Design, Development and Implementation

    June 25, 2009
    Recommendations from the ISPOR Patient Registry Classification, Strategy & Design Working Group, Team 2, for developing standard language for the characterization, classification, strategy, design, and execution of patient registries to generate data for outcomes research purposes.

  • Early phase strategies

    June 15, 2009
    Web cast about Early Phase Strategies.

  • Oversight Group Management Services

    April 16, 2009
    Quintiles provides a high level of experience, expertise and customer service to the entire clinical trial process. This is especially true for the oversight group management service, known as CEVA.

  • Risk Mitigation Programs

    April 16, 2009
    Risk mitigation measures can help keep valuable drugs on the market, even when their safety profile includes adverse events that might negatively affect the benefit risk balance.

  • Risk Assessment & Strategy

    April 16, 2009
    Quintiles benefit risk analysis can help you anticipate potential regulatory concerns and highlight the benefit side of your drug’s benefit risk profile.

  • Phase IIIb/IV Studies

    April 16, 2009
    New, more efficient delivery models help meet the increasing demands of Phase IIIB/IV Studies.

  • Late Phase and Safety Services

    April 10, 2009
    Recent and pending regulatory changes have created an atmosphere of watchful waiting throughout the industry. While it may seem premature to initiate post-marketing studies to collect more “intelligent” safety data, Quintiles Late Phase & Safety Services anticipates that the need for expanded studies will soon spread.

  • Accelerating a Trial Delayed by Slow Approvals

    March 27, 2009
    Intense remote monitoring by project coordination center quickly speeds up recruitment